Bolt Biotherapeutics(BOLT) - 2023 Q3 - Quarterly Report

Item 1A. Risk Factors. None. 31 None. X X X X SIGNATURES The following table sets forth a summary of our cash flows for each of the periods indicated: License Agreements with Stanford University FORM 10-Q | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------|-----------------------------------------|-------|-----------|--------|-------------------------------------------------------|------------------|---------|----------- ...